Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RGX-202,Bevacizumab,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna
Details : Merck gains exclusive rights to RGX-202 (ompenaclid) for RAS-mutated advanced colorectal cancer, with co-development options in the U.S.
Product Name : RGX-202
Product Type : Other Small Molecule
Upfront Cash : $45.0 million
April 01, 2024
Lead Product(s) : RGX-202,Bevacizumab,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : RGX-104,Carboplatin,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RGX-104 (abequolixron) is an orally administered small molecule agonist of the Liver X Receptor (LXR) which activates expression of the APOE tumor suppressor protein. Abequolixron is currently being tested in a Phase 1b/2 clinical trial in several lung c...
Product Name : RGX-104
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 01, 2023
Lead Product(s) : RGX-104,Carboplatin,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Sands Capital
Deal Size : $50.0 million
Deal Type : Series D Financing
Inspirna Raises $50 Million in Series D Financing
Details : Proceeds will support the development of lead candidate RGX-202-01 (“RGX-202”), an oral small molecule inhibitor of SLC6a8 to treat RAS mutant advanced colorectal cancer and RGX-104, an oral small molecule activator of LXR/APOE to treat lung and endo...
Product Name : RGX-202-01
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 07, 2022
Lead Product(s) : RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Sands Capital
Deal Size : $50.0 million
Deal Type : Series D Financing
Lead Product(s) : RGX-202-01,Irinotecan HCl Trihydrate,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RGX-202-01 is an oral, potential first-in-class small molecule inhibitor of SLC6a8, a creatine transporter that drives colorectal cancer and certain other cancers’ progression.
Product Name : RGX-202-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2022
Lead Product(s) : RGX-202-01,Irinotecan HCl Trihydrate,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RGX-202-01 is an oral, potential first-in-class small molecule inhibitor of SLC6a8, a creatine transporter that drives colorectal cancer and certain other cancers’ progression.
Product Name : RGX-202-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RGX-202-01, oral small-molecule inhibitor of SLC6A8 that induces apoptosis of colorectal cancer cell, is being tested in combination with the FOLFIRI and bevacizumab in a Phase 1b clinical trial for 2nd line treatment of patients with cancer whose tumors...
Product Name : RGX-202-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2022
Lead Product(s) : RGX-202-01,Irinotecan Hydrochloride,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable